FindTrial
Sign In

Preventive effect of coenzyme Q10 and trimetazidine on contrast-induced nephropathy in patients with renal insufficiency undergoing percutaneous coronary intervention

Preventive effect of coenzyme Q10 and trimetazidine on contrast-induced nephropathy in patients with renal insufficiency undergoing percutaneous coronary intervention

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010449
Enrollment
Unknown
Registered
2017-01-16
Start date
2017-02-20
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast-induced nephropathy

Interventions

experimental group: coenzyme Q10 and trimetazidine
control group:placebo

Sponsors

The second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Undergoing elective PCI with renal insufficiency. Renal insufficiency was defined as an estimated glomerular filtration rate (eGFR)=60mL/min/1.73m2; 2. Aged 18-75 years old, male or female; 3. signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Emergency PCI; 2. Exposed to contrast agent for 1 week; 3. Allergy to contrast agents; 4. Renal replacement therapy; 5. Acute heart failure; 6. Severe valvular heart disease; 7. Kidney or heart transplantation.

Design outcomes

Primary

MeasureTime frame
the rate of CIN;Crea;—

Secondary

MeasureTime frame
Cys-C;MACE;—

Countries

China

Contacts

Public ContactChen Fei

The second Hospital of Hebei Medical University

chenfeihebmu@aliyun.com+86 13933103302

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026